-
Previous Article
An integrated cellular and sub-cellular model of cancer chemotherapy and therapies that target cell survival
- MBE Home
- This Issue
-
Next Article
Synergistic effect of blocking cancer cell invasion revealed by computer simulations
The role of the cytokines IL-27 and IL-35 in cancer
| 1. | Mathematical Biosciences Institute, The Ohio State University, Columbus, OH 43210 |
| 2. | Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, United States |
References:
| [1] |
K. Asadullah, W. Sterry and H. D. Volk, Interleukin-10 Therapy - Review of a New Approach, Pharmacological Reviews, 55 (2003), 241-269. |
| [2] |
K. C. Boelte, L. E. Gordy, S. Joyce, M. A. Thompson, L. Yang and P. C. Lin, Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1, PLoS ONE, 6 (2011), e18534. |
| [3] |
F. Broere, S. G. Apasov, M. V. Sitkovsky and W. V. Eden, T cell subsets and T cell-mediated immunity, Principles of Immunopharmacology: 3rd revised and extended edition, 2011. |
| [4] |
M. J. Brunda, L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf and M. K. Gately, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, The Journal of Experimental Medicine, 178 (1993), 1223-1230. |
| [5] |
B. D. Car, V. M. Eng, J. M. Lipman and T. D. Anderson, The toxicology of interleukin-12: A review, Toxicologic Pathology, 27 (1999), 58-63. |
| [6] |
V. Chaturvedi, L. W. Collison, C. S. Guy, C. J. Workman and D. A. A. Vignali, Human regulatory T cells eequire Interleukin-35 to mediate suppression and infectious tolerance, J. Immunol., 186 (2011), 6661-6666. |
| [7] |
F. Cavallo, P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo and G. Forni, Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (il-12) or other cytokines compared with exogenous il-12, Journal of the National Cancer Institute, 89 (1997), 1049-1058. |
| [8] |
D. Chen, J. M. Roda, C. B. Marsh, T. D. Eubank and A. Friedman, Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: A mathematical model, Bull. Math. Biol., 74 (2012), 2752-2777. |
| [9] |
M. Chiyo, O. Shimozato, T. Lizasa, T. Fujisawa and M. Tagawa, Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells, Anticancer Res., 24 (2004), 3763-3767. |
| [10] |
C. Cocco, S. Canale, C. Frasson, E. Di Carlo, E. Ognio, D. Ribatti, I. Prigione, G. Basso and I. Airoldi, Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells, Blood, 116 (2010), 3887-3898. |
| [11] |
L. W. Collison, C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg and D. A. Vignali, The inhibitory cytokine IL-35 contributes to regulatory T-cell function, Nature, 450 (2007), 566-569. |
| [12] |
L. W. Collison and D. A. A. Vignali, Interleukin-35: Odd one out or part of the family?, Immunol. Rev., 226 (2008), 248-262. |
| [13] |
L. W. Collison, G. M. Delgoffe, C. S. Guy, K. M. Vignali, V. Chaturvedi, D. Fairweather, A. R. Satoskar, K. C. Garcia, C. A. Hunter, C. G. Drake, P. J. Murray and D. A. A. Vignali, The composition and signaling of the IL-35 receptor are unconventional, Nature immunology, 13 (2012), 290-299. |
| [14] |
M. P. Colombo and G. Trinchieri, Interleukin-12 in anti-tumor immunity and immunotherapy, Cytokine Growth Factor Rev., 13 (2002), 155-168. |
| [15] |
K. Eller, D. Wolf, J. M. Huber, M. Metz, G. Mayer, A. N. J. McKenzie, M. Maurer, A. R. Rosenkranz and A. M. Wolf, IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-onduced immune suppression. J. Immunology, 186 (2011), 83-91. |
| [16] |
T. Eubank, R. D. Roberts, M. Galoway, Y. Wang, D. Cohn and C. Marsh, GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice, Immunity, 21 (2004), 831-842. |
| [17] |
T. Eubank, R. D. Roberts, M. Khan, J. Curry, G. J. Nuovo, P. Kuppusamyl and C. Marsh, Granulocyte macrophage Colony-Stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages, Cancer Res., 69 (2009), 2133-2140. |
| [18] |
T. Eubank, J. M. Roda, H. Liu, T. O'Neil and C. Marsh, Opposing roles for HIF-1$\alpha$ and HIF-2$\alpha$ in the regulation of angiogenesis by mononuclear phagocytes, Blood, 117 (2011), 323-331. |
| [19] |
S. Fujii, K. Shimizu, T. Shimizu and M. T. Lotze, Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ, Blood, 98 (2001), 2143-2151. |
| [20] |
D. I. Gabrilovich, S. O. Rosenberg and V. Bronte, Coordinated regulation of myeloid cells by tumors, Nat. Rev. Immunol., 12 (2012), 253-268. |
| [21] |
H. Groux, M. Bigler, J. E. Vries and M. G. Roncarolo, Inhibitory and Stimulatory Effects of IL-10 on Human CD8$^+$ T Cells, J Immunol, 160 (1998), 3188-3193. |
| [22] |
H. Grous, F. Coottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, M. Bigler, M. G. Roncarolo and R. L. Coffman, A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells, J. Immunol, 162 (1999), 1723-1729. |
| [23] |
M. Hisada, S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi and T. Yoshimoto, Potent antitumor activity of interleukin-27, Cancer Res, 64 (2004), 1152-1156. |
| [24] |
M. Y. Ho, S. J. Leu, G. H. Sun, M. H. Tao, S. J. Tang and K. H. Sun, IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities, J. Immunol., 183 (2009), 6217-6226. |
| [25] |
C. A. Hunter, New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions, Nat Rev Immunol, 5 (2005), 521-531. |
| [26] |
E. Itakura, R. R. Huang, D. R. Wen, E. Paul, P. Wünsch and A. J. Cochran, IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence, Modern Pathology, 24 (2011), 801-809. |
| [27] |
T. Kaiga, M. Sato, H. Kaneda, Y. Iwakura, T. Takayama and H. Tahara, Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12, J Immunol., 178 (2007), 7571-7580. |
| [28] |
K. W. Kross, J. H. Heimdal, C. Olsnes, J. Olofson and H. J. Aarstad, Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue, Acta Otolaryngol, 127 (2007), 532-539. |
| [29] |
H. H. Lee, S. S. Yang, M. T. Vo, W. J. Cho, B. J. Lee, S. H. Leem, S. H. Lee, H. J. Cha and J. W. Park, Tristetraprolin down-regulates IL-23 expression in colon cancer cells, Mol. Cells, 36 (2013), 571-576. |
| [30] |
J. Li, L. Zhang, J. Zhang, Y. Wei, K. Li, L. Huang, S. Zhang, B. Gao, X. Wang and P. Lin, Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor, Carcinogenesis, 34 (2012), 658-666. |
| [31] |
K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin-27 induction of anti-tumor T cells response, PLoS ONE, 9 (2014), e91844. |
| [32] |
K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin 35 promoting tumor growth and angiogenesis, PLoS ONE, 9 (2014), e110126. |
| [33] |
Z. Liu, J.-Q. Liu, F. Talebian, L.-C. Wu, S. Li and X.-F. Bai, IL-27 enhances the survival of tumor antigen-specific CD8$^+$ T cells and programs them into IL-10-producing, memory precursor-like effector cells, European J. of Immunology, 43 (2013), 468-479. |
| [34] |
U. K. Liyanage, T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure and D. C. Linehan, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J. Immunol., 169 (2002), 2756-2761. |
| [35] |
J. Long, X. Zhang, M. Wena, Q. Kong, Z. Lv, Y. An and X.-Q. Wei, IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells, Biochemical and Biophysical Research Communications, 430 (2013), 364-369. |
| [36] |
K. Loser and S. Beissert, Regulatory T Cells: Banned Cells for Decades, J. Investigative Dermatology, 132 (2012), 864-871. |
| [37] |
Y. Louzoun, C. Xue, G. B. Lesinski and A. Friedman, A mathematical model for pancreatic cancer growth and treatments, J. Theor. Biol., 351 (2014), 74-82.
doi: 10.1016/j.jtbi.2014.02.028. |
| [38] |
T. A. Mace, Z. Ameen, A. Collins, S. E. Wojcik, M. Mair, G. S. Young, J. R. Fuchs, T. D. Eubank, W. L. Frankel, T. Bekaii-Saab, M. Bloomston and G. B. Lesinski, Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a stat3-dependent manner, Cancer Res., 73 (2013), 3007-3018. |
| [39] |
E. Marshall, Cancer trial of interleukin-12 halted, Science (Wash DC), 268 (1995), p1555. |
| [40] |
N. Morishima, I. Mizoguchi, M. Okumura, Y. Chiba, M. Shimizu, M. Xu, M. Matsui, J. Mizuguchi and T. Yoshimoto, A prvotal role for interleukin-27 in CD8$^+$ T cell functions and generation of cutotoxic T lymphocytes, J. Biomed Biotechnol, 2010 (2010), Article ID 605483, 10 pages.
doi: 10.1155/2010/605483. |
| [41] |
J. B. Mumm, J. Emmerich, X. Zhang, I. Chan, L. Mauze, S. Wu, S. Blaisdell, B. Basham, J. Dai, J. Grein, C. Sheppard, K. Hong, C. Cutler, S. Turner, D. Laface, M. Kleinscher, M. Judo, G. Ayanoglu, J. Langowski, D. Paporello, B. Gu, E. Murphy, V. Sriram, S. Naravula, B. Desai, S. Medicherla, W. Seghezzi, T. McClanahan, S. Csnnon-Carlson, A. M. Beebe and M. Oft, IL-10 elicits IFN-$\gamma$-dependent tumor immune surveillance, Cancer Cell, 20 (2011), 781-796. |
| [42] |
M. B. Omary, A. Lugea, A. W. Lowe and S. J. Pandol, The pancreatic stellate cell: a star on the rise in pancreatic diseases, J. Clin Invest., 117 (2007), 50-59. |
| [43] |
J. G. Quatromoni, E. Suzuki, O. Okusanya, B. F. Judy, P. Bhojnagarwala, O. Venegas, E. Eruslanov, J. D. Predina, S. M. Albelda and S. Singhal, The timing of TGF-$\beta$ inhibition affects the generation of antigen-specific CD8$^+$ T cells, BMC Immunol, 14 (2013), p30.
doi: 10.1186/1471-2172-14-30. |
| [44] |
A. L. Rakhmilevich, K. Janssen, J. Turner, J. Culp and N. S. Yang, Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12, Hum Gene Ther, 8 (1997), 1303-1311. |
| [45] |
J. C. Reay, Therapeutic gene therapy for cancer with interleukin-23,, 2010., ().
|
| [46] |
S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin and T. Yamaguchi, Regulatory T cells: how do they suppress immune responses?, International Immunology, 21 (2012), 1105-1111. |
| [47] |
R. Salcedo, J. A. Hixon, J. K. Stauffer, R. Jalah, A. D. Brooks, T. Khan, R. M. Dai, L. Scheetz, E. Lincoln, T. C. Back, D. Powell, A. A. Hurwitz, T. J. Sayers, R. Kastelein, G. N. Pavlakis, B. K. Felber, G. Trinchieri and J. M. Wigginton, Immunologic and therapeutic synergy of IL-27 and IL-2: Ehancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow, J. Immunol., 182 (2009), 4328-4338. |
| [48] |
R. Salcedo, J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein and J. M. Wigginton, IL-27 mediated complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8$^+$ T cells, J. Immunol., 173 (2004), 7170-7182. |
| [49] |
F. W. Shek, R. C. Benyon, F. M. Walker, P. R. McCrudden, S. L. Pender, E. J. Williams, P. A. Johnson, C. D. Johnson, A. C. Bateman, D. R. Fine and J. P. Iredale, Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis, Am. J. Pathol., 160 (2002), 1787-1798. |
| [50] |
Y. Shinozaki, S. Wang, Y. Miyazaki, K. Miyazaki, H. Yamada, Y. Yoshikai, H. Hara and H. Yoshida, Tumor-specific cutotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity, Int. J. Cancer, 124 (2009), 1372-1378. |
| [51] |
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson and T. L. Whiteside, A Unique subset of CD4$^+$$CD25^{high}$Fox $p3^{+}$ T cells secreting Interleukin-10 and transforming growth factor-$\beta 1$ mediates suppression in the tumor microenvironment, Clinical Cancer Research, 13 (2007), 4345-4354. |
| [52] |
A. Swarbrick, S. R. Junankar and M. Batten, Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?, Oncoimmunology, 2 (2013), e25409. |
| [53] |
B. Szomolay, T. Eubank, R. Roberts, C. Marsh and A. Friedman, Modeling the inhibition of breast cancer growth by GM-CSF, J. Theor. Biol., 303 (2012), 141-151.
doi: 10.1016/j.jtbi.2012.03.024. |
| [54] |
T. Tanikawa, C. M. Wilke, I. Kryczek, G. Y. Chen, J. Kao, G. Nú$\ddotn$ez and W. Zou, Interleukin-10 anlation promotes tumor developments, growth, and metastasis, Cancer Res., 72 (2012), 420-429. |
| [55] |
M. W. Teng, M. D. Vesely, H. Duret, N. McLaughlin, J. E. Towne, R. D. Schreiber and M. J. Smyth, Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state, Cancer Res., 72 (2012), 3987-3996. |
| [56] |
D. A. Thomas and J. Massagué, TGF-$\beta$ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, 8 (2005), 369-380. |
| [57] |
M. M. Tiemessen, S. Kunzmann, C. B. Schmidt-Weber, J. Garssen, C. A. Bruijnzeel-Koomen, E. F. Knol and E. van Hoffen, Transforming growth factor-beta inhibits human antigen-specific CD4$^+$ T cell proliferation without modulating the cytokine response, Int Immunol, 14 (2003), 1495-1504. |
| [58] |
D. A. A. Vignali, L. W. Collison and C. J. Workman, How regulatory T cells work, Nat. Rev. Immunol., 8 (2008), 523-532. |
| [59] |
D. A. A. Vignali and V. K. Kuchroo, IL-12 family cytokines: Immunological playmakers, Nature immunology, 13 (2012), 722-728. |
| [60] |
R. Wang, M. Lu, J. Zhang, S. Chen, X. Luo, Y. Qin and H. Chen, Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer, J. Experimental and Clinical Cancer Research, 30 (2011), p62.
doi: 10.1186/1756-9966-30-62. |
| [61] |
V. Wang, J. Q. Liu, Z. Liu, R. Shen, G. Zhang, J. Xu, Y. Fend and X. F. Bai, Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis, J. Immuno., (2013). |
| [62] |
E. D. Wojno, N. Hosken, J. S. Stumhofer, A. C. O'Hara, E. Mauldin, Q. Fang, L. A. Turka, S. D. Levin and C. A. Hunter, A role for IL-27 in limiting T regulatory cell populations, J Immunol, 187 (2011), 266-273. |
| [63] |
D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius and C. Marth, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer, Clin. Cancer Res., 11 (2005), 8326-8331. |
| [64] |
M. Xu, I. Mizoguchi, N. Morishima, Y. Chiba, J. Mizuguchi and T. Yoshimoto, Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27, Clinical and Developmental immunology, 2010 (2010), Article ID 832454, 9 pages.
doi: 10.1155/2010/832454. |
| [65] |
W. C. Yang, G. Ma, S. H. Chen and P. Y. Pan, Polarization and reprogramming of myeloid-derived suppressor cells, J. Mol Cell Biol., 5 (2013), 207-209. |
| [66] |
N. G. Yousif, S. Alhasani, H. Slimani, J. Doug, B. I. Mohammad, S. Machil, A. A. Deb and N. Romalid, The role of IL-23 in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling, 2014 Genitourinary Cancer Symposium, 2014. |
| [67] |
J.-C. Zeng, Z. Zhang, T.-Y. Li, Y.-F. Liang, H.-M. Wang, J.-J. Bao, J.-A. Zhang, W.-D. Wang, W.-Y. Xiang, B. Kong, Z.-Y. Wang, B.-H. Wu, X.-D. Chen, L. He, S. Zhang, C.-Y. Wang and J.-F. Xu, Assessing the role of IL-35 in colorectal cancer progression and prognosis, Int J Clin Exp Pathol, 6 (2013), 1806-1816. |
| [68] |
S. Zhu, D. A. Lee and S. Li, IL-12 and IL-27 sequential gene therapy via intramuscular eletroporation delivery for eliminating distal aggressive tumors, J. Immunol., 184 (2010), 2348-2354. |
| [69] |
O. Zolochevska, A. O. Diaz-Qui$\ddotn$ones, J. Ellis and M. L. Figueiredo, Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro, J. Cell Physiol., 228 (2013), 1127-1136. |
show all references
References:
| [1] |
K. Asadullah, W. Sterry and H. D. Volk, Interleukin-10 Therapy - Review of a New Approach, Pharmacological Reviews, 55 (2003), 241-269. |
| [2] |
K. C. Boelte, L. E. Gordy, S. Joyce, M. A. Thompson, L. Yang and P. C. Lin, Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1, PLoS ONE, 6 (2011), e18534. |
| [3] |
F. Broere, S. G. Apasov, M. V. Sitkovsky and W. V. Eden, T cell subsets and T cell-mediated immunity, Principles of Immunopharmacology: 3rd revised and extended edition, 2011. |
| [4] |
M. J. Brunda, L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf and M. K. Gately, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, The Journal of Experimental Medicine, 178 (1993), 1223-1230. |
| [5] |
B. D. Car, V. M. Eng, J. M. Lipman and T. D. Anderson, The toxicology of interleukin-12: A review, Toxicologic Pathology, 27 (1999), 58-63. |
| [6] |
V. Chaturvedi, L. W. Collison, C. S. Guy, C. J. Workman and D. A. A. Vignali, Human regulatory T cells eequire Interleukin-35 to mediate suppression and infectious tolerance, J. Immunol., 186 (2011), 6661-6666. |
| [7] |
F. Cavallo, P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo and G. Forni, Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (il-12) or other cytokines compared with exogenous il-12, Journal of the National Cancer Institute, 89 (1997), 1049-1058. |
| [8] |
D. Chen, J. M. Roda, C. B. Marsh, T. D. Eubank and A. Friedman, Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: A mathematical model, Bull. Math. Biol., 74 (2012), 2752-2777. |
| [9] |
M. Chiyo, O. Shimozato, T. Lizasa, T. Fujisawa and M. Tagawa, Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells, Anticancer Res., 24 (2004), 3763-3767. |
| [10] |
C. Cocco, S. Canale, C. Frasson, E. Di Carlo, E. Ognio, D. Ribatti, I. Prigione, G. Basso and I. Airoldi, Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells, Blood, 116 (2010), 3887-3898. |
| [11] |
L. W. Collison, C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg and D. A. Vignali, The inhibitory cytokine IL-35 contributes to regulatory T-cell function, Nature, 450 (2007), 566-569. |
| [12] |
L. W. Collison and D. A. A. Vignali, Interleukin-35: Odd one out or part of the family?, Immunol. Rev., 226 (2008), 248-262. |
| [13] |
L. W. Collison, G. M. Delgoffe, C. S. Guy, K. M. Vignali, V. Chaturvedi, D. Fairweather, A. R. Satoskar, K. C. Garcia, C. A. Hunter, C. G. Drake, P. J. Murray and D. A. A. Vignali, The composition and signaling of the IL-35 receptor are unconventional, Nature immunology, 13 (2012), 290-299. |
| [14] |
M. P. Colombo and G. Trinchieri, Interleukin-12 in anti-tumor immunity and immunotherapy, Cytokine Growth Factor Rev., 13 (2002), 155-168. |
| [15] |
K. Eller, D. Wolf, J. M. Huber, M. Metz, G. Mayer, A. N. J. McKenzie, M. Maurer, A. R. Rosenkranz and A. M. Wolf, IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-onduced immune suppression. J. Immunology, 186 (2011), 83-91. |
| [16] |
T. Eubank, R. D. Roberts, M. Galoway, Y. Wang, D. Cohn and C. Marsh, GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice, Immunity, 21 (2004), 831-842. |
| [17] |
T. Eubank, R. D. Roberts, M. Khan, J. Curry, G. J. Nuovo, P. Kuppusamyl and C. Marsh, Granulocyte macrophage Colony-Stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages, Cancer Res., 69 (2009), 2133-2140. |
| [18] |
T. Eubank, J. M. Roda, H. Liu, T. O'Neil and C. Marsh, Opposing roles for HIF-1$\alpha$ and HIF-2$\alpha$ in the regulation of angiogenesis by mononuclear phagocytes, Blood, 117 (2011), 323-331. |
| [19] |
S. Fujii, K. Shimizu, T. Shimizu and M. T. Lotze, Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ, Blood, 98 (2001), 2143-2151. |
| [20] |
D. I. Gabrilovich, S. O. Rosenberg and V. Bronte, Coordinated regulation of myeloid cells by tumors, Nat. Rev. Immunol., 12 (2012), 253-268. |
| [21] |
H. Groux, M. Bigler, J. E. Vries and M. G. Roncarolo, Inhibitory and Stimulatory Effects of IL-10 on Human CD8$^+$ T Cells, J Immunol, 160 (1998), 3188-3193. |
| [22] |
H. Grous, F. Coottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, M. Bigler, M. G. Roncarolo and R. L. Coffman, A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells, J. Immunol, 162 (1999), 1723-1729. |
| [23] |
M. Hisada, S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi and T. Yoshimoto, Potent antitumor activity of interleukin-27, Cancer Res, 64 (2004), 1152-1156. |
| [24] |
M. Y. Ho, S. J. Leu, G. H. Sun, M. H. Tao, S. J. Tang and K. H. Sun, IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities, J. Immunol., 183 (2009), 6217-6226. |
| [25] |
C. A. Hunter, New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions, Nat Rev Immunol, 5 (2005), 521-531. |
| [26] |
E. Itakura, R. R. Huang, D. R. Wen, E. Paul, P. Wünsch and A. J. Cochran, IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence, Modern Pathology, 24 (2011), 801-809. |
| [27] |
T. Kaiga, M. Sato, H. Kaneda, Y. Iwakura, T. Takayama and H. Tahara, Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12, J Immunol., 178 (2007), 7571-7580. |
| [28] |
K. W. Kross, J. H. Heimdal, C. Olsnes, J. Olofson and H. J. Aarstad, Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue, Acta Otolaryngol, 127 (2007), 532-539. |
| [29] |
H. H. Lee, S. S. Yang, M. T. Vo, W. J. Cho, B. J. Lee, S. H. Leem, S. H. Lee, H. J. Cha and J. W. Park, Tristetraprolin down-regulates IL-23 expression in colon cancer cells, Mol. Cells, 36 (2013), 571-576. |
| [30] |
J. Li, L. Zhang, J. Zhang, Y. Wei, K. Li, L. Huang, S. Zhang, B. Gao, X. Wang and P. Lin, Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor, Carcinogenesis, 34 (2012), 658-666. |
| [31] |
K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin-27 induction of anti-tumor T cells response, PLoS ONE, 9 (2014), e91844. |
| [32] |
K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin 35 promoting tumor growth and angiogenesis, PLoS ONE, 9 (2014), e110126. |
| [33] |
Z. Liu, J.-Q. Liu, F. Talebian, L.-C. Wu, S. Li and X.-F. Bai, IL-27 enhances the survival of tumor antigen-specific CD8$^+$ T cells and programs them into IL-10-producing, memory precursor-like effector cells, European J. of Immunology, 43 (2013), 468-479. |
| [34] |
U. K. Liyanage, T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure and D. C. Linehan, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J. Immunol., 169 (2002), 2756-2761. |
| [35] |
J. Long, X. Zhang, M. Wena, Q. Kong, Z. Lv, Y. An and X.-Q. Wei, IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells, Biochemical and Biophysical Research Communications, 430 (2013), 364-369. |
| [36] |
K. Loser and S. Beissert, Regulatory T Cells: Banned Cells for Decades, J. Investigative Dermatology, 132 (2012), 864-871. |
| [37] |
Y. Louzoun, C. Xue, G. B. Lesinski and A. Friedman, A mathematical model for pancreatic cancer growth and treatments, J. Theor. Biol., 351 (2014), 74-82.
doi: 10.1016/j.jtbi.2014.02.028. |
| [38] |
T. A. Mace, Z. Ameen, A. Collins, S. E. Wojcik, M. Mair, G. S. Young, J. R. Fuchs, T. D. Eubank, W. L. Frankel, T. Bekaii-Saab, M. Bloomston and G. B. Lesinski, Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a stat3-dependent manner, Cancer Res., 73 (2013), 3007-3018. |
| [39] |
E. Marshall, Cancer trial of interleukin-12 halted, Science (Wash DC), 268 (1995), p1555. |
| [40] |
N. Morishima, I. Mizoguchi, M. Okumura, Y. Chiba, M. Shimizu, M. Xu, M. Matsui, J. Mizuguchi and T. Yoshimoto, A prvotal role for interleukin-27 in CD8$^+$ T cell functions and generation of cutotoxic T lymphocytes, J. Biomed Biotechnol, 2010 (2010), Article ID 605483, 10 pages.
doi: 10.1155/2010/605483. |
| [41] |
J. B. Mumm, J. Emmerich, X. Zhang, I. Chan, L. Mauze, S. Wu, S. Blaisdell, B. Basham, J. Dai, J. Grein, C. Sheppard, K. Hong, C. Cutler, S. Turner, D. Laface, M. Kleinscher, M. Judo, G. Ayanoglu, J. Langowski, D. Paporello, B. Gu, E. Murphy, V. Sriram, S. Naravula, B. Desai, S. Medicherla, W. Seghezzi, T. McClanahan, S. Csnnon-Carlson, A. M. Beebe and M. Oft, IL-10 elicits IFN-$\gamma$-dependent tumor immune surveillance, Cancer Cell, 20 (2011), 781-796. |
| [42] |
M. B. Omary, A. Lugea, A. W. Lowe and S. J. Pandol, The pancreatic stellate cell: a star on the rise in pancreatic diseases, J. Clin Invest., 117 (2007), 50-59. |
| [43] |
J. G. Quatromoni, E. Suzuki, O. Okusanya, B. F. Judy, P. Bhojnagarwala, O. Venegas, E. Eruslanov, J. D. Predina, S. M. Albelda and S. Singhal, The timing of TGF-$\beta$ inhibition affects the generation of antigen-specific CD8$^+$ T cells, BMC Immunol, 14 (2013), p30.
doi: 10.1186/1471-2172-14-30. |
| [44] |
A. L. Rakhmilevich, K. Janssen, J. Turner, J. Culp and N. S. Yang, Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12, Hum Gene Ther, 8 (1997), 1303-1311. |
| [45] |
J. C. Reay, Therapeutic gene therapy for cancer with interleukin-23,, 2010., ().
|
| [46] |
S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin and T. Yamaguchi, Regulatory T cells: how do they suppress immune responses?, International Immunology, 21 (2012), 1105-1111. |
| [47] |
R. Salcedo, J. A. Hixon, J. K. Stauffer, R. Jalah, A. D. Brooks, T. Khan, R. M. Dai, L. Scheetz, E. Lincoln, T. C. Back, D. Powell, A. A. Hurwitz, T. J. Sayers, R. Kastelein, G. N. Pavlakis, B. K. Felber, G. Trinchieri and J. M. Wigginton, Immunologic and therapeutic synergy of IL-27 and IL-2: Ehancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow, J. Immunol., 182 (2009), 4328-4338. |
| [48] |
R. Salcedo, J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein and J. M. Wigginton, IL-27 mediated complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8$^+$ T cells, J. Immunol., 173 (2004), 7170-7182. |
| [49] |
F. W. Shek, R. C. Benyon, F. M. Walker, P. R. McCrudden, S. L. Pender, E. J. Williams, P. A. Johnson, C. D. Johnson, A. C. Bateman, D. R. Fine and J. P. Iredale, Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis, Am. J. Pathol., 160 (2002), 1787-1798. |
| [50] |
Y. Shinozaki, S. Wang, Y. Miyazaki, K. Miyazaki, H. Yamada, Y. Yoshikai, H. Hara and H. Yoshida, Tumor-specific cutotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity, Int. J. Cancer, 124 (2009), 1372-1378. |
| [51] |
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson and T. L. Whiteside, A Unique subset of CD4$^+$$CD25^{high}$Fox $p3^{+}$ T cells secreting Interleukin-10 and transforming growth factor-$\beta 1$ mediates suppression in the tumor microenvironment, Clinical Cancer Research, 13 (2007), 4345-4354. |
| [52] |
A. Swarbrick, S. R. Junankar and M. Batten, Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?, Oncoimmunology, 2 (2013), e25409. |
| [53] |
B. Szomolay, T. Eubank, R. Roberts, C. Marsh and A. Friedman, Modeling the inhibition of breast cancer growth by GM-CSF, J. Theor. Biol., 303 (2012), 141-151.
doi: 10.1016/j.jtbi.2012.03.024. |
| [54] |
T. Tanikawa, C. M. Wilke, I. Kryczek, G. Y. Chen, J. Kao, G. Nú$\ddotn$ez and W. Zou, Interleukin-10 anlation promotes tumor developments, growth, and metastasis, Cancer Res., 72 (2012), 420-429. |
| [55] |
M. W. Teng, M. D. Vesely, H. Duret, N. McLaughlin, J. E. Towne, R. D. Schreiber and M. J. Smyth, Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state, Cancer Res., 72 (2012), 3987-3996. |
| [56] |
D. A. Thomas and J. Massagué, TGF-$\beta$ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, 8 (2005), 369-380. |
| [57] |
M. M. Tiemessen, S. Kunzmann, C. B. Schmidt-Weber, J. Garssen, C. A. Bruijnzeel-Koomen, E. F. Knol and E. van Hoffen, Transforming growth factor-beta inhibits human antigen-specific CD4$^+$ T cell proliferation without modulating the cytokine response, Int Immunol, 14 (2003), 1495-1504. |
| [58] |
D. A. A. Vignali, L. W. Collison and C. J. Workman, How regulatory T cells work, Nat. Rev. Immunol., 8 (2008), 523-532. |
| [59] |
D. A. A. Vignali and V. K. Kuchroo, IL-12 family cytokines: Immunological playmakers, Nature immunology, 13 (2012), 722-728. |
| [60] |
R. Wang, M. Lu, J. Zhang, S. Chen, X. Luo, Y. Qin and H. Chen, Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer, J. Experimental and Clinical Cancer Research, 30 (2011), p62.
doi: 10.1186/1756-9966-30-62. |
| [61] |
V. Wang, J. Q. Liu, Z. Liu, R. Shen, G. Zhang, J. Xu, Y. Fend and X. F. Bai, Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis, J. Immuno., (2013). |
| [62] |
E. D. Wojno, N. Hosken, J. S. Stumhofer, A. C. O'Hara, E. Mauldin, Q. Fang, L. A. Turka, S. D. Levin and C. A. Hunter, A role for IL-27 in limiting T regulatory cell populations, J Immunol, 187 (2011), 266-273. |
| [63] |
D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius and C. Marth, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer, Clin. Cancer Res., 11 (2005), 8326-8331. |
| [64] |
M. Xu, I. Mizoguchi, N. Morishima, Y. Chiba, J. Mizuguchi and T. Yoshimoto, Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27, Clinical and Developmental immunology, 2010 (2010), Article ID 832454, 9 pages.
doi: 10.1155/2010/832454. |
| [65] |
W. C. Yang, G. Ma, S. H. Chen and P. Y. Pan, Polarization and reprogramming of myeloid-derived suppressor cells, J. Mol Cell Biol., 5 (2013), 207-209. |
| [66] |
N. G. Yousif, S. Alhasani, H. Slimani, J. Doug, B. I. Mohammad, S. Machil, A. A. Deb and N. Romalid, The role of IL-23 in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling, 2014 Genitourinary Cancer Symposium, 2014. |
| [67] |
J.-C. Zeng, Z. Zhang, T.-Y. Li, Y.-F. Liang, H.-M. Wang, J.-J. Bao, J.-A. Zhang, W.-D. Wang, W.-Y. Xiang, B. Kong, Z.-Y. Wang, B.-H. Wu, X.-D. Chen, L. He, S. Zhang, C.-Y. Wang and J.-F. Xu, Assessing the role of IL-35 in colorectal cancer progression and prognosis, Int J Clin Exp Pathol, 6 (2013), 1806-1816. |
| [68] |
S. Zhu, D. A. Lee and S. Li, IL-12 and IL-27 sequential gene therapy via intramuscular eletroporation delivery for eliminating distal aggressive tumors, J. Immunol., 184 (2010), 2348-2354. |
| [69] |
O. Zolochevska, A. O. Diaz-Qui$\ddotn$ones, J. Ellis and M. L. Figueiredo, Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro, J. Cell Physiol., 228 (2013), 1127-1136. |
| [1] |
Urszula Foryś, Jan Poleszczuk. A delay-differential equation model of HIV related cancer--immune system dynamics. Mathematical Biosciences & Engineering, 2011, 8 (2) : 627-641. doi: 10.3934/mbe.2011.8.627 |
| [2] |
Dan Liu, Shigui Ruan, Deming Zhu. Stable periodic oscillations in a two-stage cancer model of tumor and immune system interactions. Mathematical Biosciences & Engineering, 2012, 9 (2) : 347-368. doi: 10.3934/mbe.2012.9.347 |
| [3] |
Marcello Delitala, Tommaso Lorenzi. Recognition and learning in a mathematical model for immune response against cancer. Discrete and Continuous Dynamical Systems - B, 2013, 18 (4) : 891-914. doi: 10.3934/dcdsb.2013.18.891 |
| [4] |
Jianhong Wu, Weiguang Yao, Huaiping Zhu. Immune system memory realization in a population model. Discrete and Continuous Dynamical Systems - B, 2007, 8 (1) : 241-259. doi: 10.3934/dcdsb.2007.8.241 |
| [5] |
Mika Yoshida, Kinji Fuchikami, Tatsuya Uezu. Realization of immune response features by dynamical system models. Mathematical Biosciences & Engineering, 2007, 4 (3) : 531-552. doi: 10.3934/mbe.2007.4.531 |
| [6] |
Alberto d'Onofrio. On the interaction between the immune system and an exponentially replicating pathogen. Mathematical Biosciences & Engineering, 2010, 7 (3) : 579-602. doi: 10.3934/mbe.2010.7.579 |
| [7] |
Dan Liu, Shigui Ruan, Deming Zhu. Bifurcation analysis in models of tumor and immune system interactions. Discrete and Continuous Dynamical Systems - B, 2009, 12 (1) : 151-168. doi: 10.3934/dcdsb.2009.12.151 |
| [8] |
Nasser Sweilam, Fathalla Rihan, Seham AL-Mekhlafi. A fractional-order delay differential model with optimal control for cancer treatment based on synergy between anti-angiogenic and immune cell therapies. Discrete and Continuous Dynamical Systems - S, 2020, 13 (9) : 2403-2424. doi: 10.3934/dcdss.2020120 |
| [9] |
Giulio Caravagna, Alex Graudenzi, Alberto d’Onofrio. Distributed delays in a hybrid model of tumor-Immune system interplay. Mathematical Biosciences & Engineering, 2013, 10 (1) : 37-57. doi: 10.3934/mbe.2013.10.37 |
| [10] |
Yueping Dong, Rinko Miyazaki, Yasuhiro Takeuchi. Mathematical modeling on helper T cells in a tumor immune system. Discrete and Continuous Dynamical Systems - B, 2014, 19 (1) : 55-72. doi: 10.3934/dcdsb.2014.19.55 |
| [11] |
Shigui Ruan. Nonlinear dynamics in tumor-immune system interaction models with delays. Discrete and Continuous Dynamical Systems - B, 2021, 26 (1) : 541-602. doi: 10.3934/dcdsb.2020282 |
| [12] |
Mengshi Shu, Rui Fu, Wendi Wang. A bacteriophage model based on CRISPR/Cas immune system in a chemostat. Mathematical Biosciences & Engineering, 2017, 14 (5&6) : 1361-1377. doi: 10.3934/mbe.2017070 |
| [13] |
Gladis Torres-Espino, Claudio Vidal. Periodic solutions of a tumor-immune system interaction under a periodic immunotherapy. Discrete and Continuous Dynamical Systems - B, 2021, 26 (8) : 4523-4547. doi: 10.3934/dcdsb.2020301 |
| [14] |
Sophia R-J Jang, Hsiu-Chuan Wei. On a mathematical model of tumor-immune system interactions with an oncolytic virus therapy. Discrete and Continuous Dynamical Systems - B, 2022, 27 (6) : 3261-3295. doi: 10.3934/dcdsb.2021184 |
| [15] |
Manuel Delgado, Ítalo Bruno Mendes Duarte, Antonio Suárez Fernández. Nonlocal elliptic system arising from the growth of cancer stem cells. Discrete and Continuous Dynamical Systems - B, 2018, 23 (4) : 1767-1795. doi: 10.3934/dcdsb.2018083 |
| [16] |
Martina Conte, Maria Groppi, Giampiero Spiga. Qualitative analysis of kinetic-based models for tumor-immune system interaction. Discrete and Continuous Dynamical Systems - B, 2018, 23 (6) : 2393-2414. doi: 10.3934/dcdsb.2018060 |
| [17] |
Min Yu, Gang Huang, Yueping Dong, Yasuhiro Takeuchi. Complicated dynamics of tumor-immune system interaction model with distributed time delay. Discrete and Continuous Dynamical Systems - B, 2020, 25 (7) : 2391-2406. doi: 10.3934/dcdsb.2020015 |
| [18] |
Urszula Ledzewicz, Omeiza Olumoye, Heinz Schättler. On optimal chemotherapy with a strongly targeted agent for a model of tumor-immune system interactions with generalized logistic growth. Mathematical Biosciences & Engineering, 2013, 10 (3) : 787-802. doi: 10.3934/mbe.2013.10.787 |
| [19] |
Jianquan Li, Xin Xie, Dian Zhang, Jia Li, Xiaolin Lin. Qualitative analysis of a simple tumor-immune system with time delay of tumor action. Discrete and Continuous Dynamical Systems - B, 2021, 26 (10) : 5227-5249. doi: 10.3934/dcdsb.2020341 |
| [20] |
Jianquan Li, Xiangxiang Ma, Yuming Chen, Dian Zhang. Complex dynamic behaviors of a tumor-immune system with two delays in tumor actions. Discrete and Continuous Dynamical Systems - B, 2022 doi: 10.3934/dcdsb.2022033 |
2018 Impact Factor: 1.313
Tools
Metrics
Other articles
by authors
[Back to Top]